Mirte R Caanen1, Remi S Soleman2, Esther A M Kuijper3, Baudewijntje P C Kreukels4, Chloë De Roo5, Kelly Tilleman5, Petra De Sutter5, Mick A A van Trotsenburg6, Frank J Broekmans7, Cornelis B Lambalk8. 1. Division of Reproductive Medicine, Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, the Netherlands. Electronic address: m.caanen@vumc.nl. 2. Division of Reproductive Medicine, Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, the Netherlands; Center of Expertise on Gender Dysphoria, VU University Medical Center, Amsterdam, the Netherlands; Department of Medical Psychology, VU University Medical Center, Amsterdam, the Netherlands. 3. Division of Reproductive Medicine, Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, the Netherlands. 4. Center of Expertise on Gender Dysphoria, VU University Medical Center, Amsterdam, the Netherlands; Department of Medical Psychology, VU University Medical Center, Amsterdam, the Netherlands. 5. Department of Reproductive Medicine, University Hospital Ghent, Ghent, Belgium. 6. Division of Reproductive Medicine, Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, the Netherlands; Center of Expertise on Gender Dysphoria, VU University Medical Center, Amsterdam, the Netherlands. 7. Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht, Utrecht, the Netherlands. 8. Division of Reproductive Medicine, Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, the Netherlands; Department of Reproductive Medicine, University Hospital Ghent, Ghent, Belgium.
Abstract
OBJECTIVE: To investigate the effect of hormonal androgenic treatment on antimüllerian hormone (AMH) serum levels in female-to-male (FtM) transsexuals. Polycystic ovary syndrome (PCOS) is associated with elevated AMH levels. Some hypothesize that the high AMH level is a consequence of androgen-induced excessive development of small antral follicles. However, this role of androgens is not yet clear. DESIGN: Observational, prospective, cohort study. SETTING: Tertiary academic medical center. PATIENT(S): Twenty-two FtM transsexuals, healthy native females receiving cross-sex hormone therapy/androgenic treatment. INTERVENTION(S): Androgenic treatment with testosterone (T) and an aromatase inhibitor while endogenous hormone secretion was suppressed with the use of a GnRH agonist. MAIN OUTCOME MEASURE(S): Hormone concentrations were measured before and after androgenic treatment (administration of T and aromatase inhibitor). Measured hormones: AMH, inhibin B, T, androstenedione, DHEAS, E2, SHBG, LH, and FSH. RESULT(S): AMH concentrations were significantly lower after androgenic treatment (4.4 ± 4.4 μg/L vs. 1.4 ± 2.1 μg/L). Androgenic treatment resulted in a strong suppression of AMH secretion over a relative short period of 16 weeks. CONCLUSION(S): Our data underscore the likely important role of androgens in the dynamics of folliculogenesis. It challenges the idea that androgens induce high AMH levels, which is gaining more interest nowadays as an important particular PCOS feature. This strong decline furthermore indicates that AMH must be interpreted in the context of other reproductive endocrine conditions. CLINICAL TRIAL REGISTRATION NUMBER: NTR2493.
OBJECTIVE: To investigate the effect of hormonal androgenic treatment on antimüllerian hormone (AMH) serum levels in female-to-male (FtM) transsexuals. Polycystic ovary syndrome (PCOS) is associated with elevated AMH levels. Some hypothesize that the high AMH level is a consequence of androgen-induced excessive development of small antral follicles. However, this role of androgens is not yet clear. DESIGN: Observational, prospective, cohort study. SETTING: Tertiary academic medical center. PATIENT(S): Twenty-two FtM transsexuals, healthy native females receiving cross-sex hormone therapy/androgenic treatment. INTERVENTION(S): Androgenic treatment with testosterone (T) and an aromatase inhibitor while endogenous hormone secretion was suppressed with the use of a GnRH agonist. MAIN OUTCOME MEASURE(S): Hormone concentrations were measured before and after androgenic treatment (administration of T and aromatase inhibitor). Measured hormones: AMH, inhibin B, T, androstenedione, DHEAS, E2, SHBG, LH, and FSH. RESULT(S): AMH concentrations were significantly lower after androgenic treatment (4.4 ± 4.4 μg/L vs. 1.4 ± 2.1 μg/L). Androgenic treatment resulted in a strong suppression of AMH secretion over a relative short period of 16 weeks. CONCLUSION(S): Our data underscore the likely important role of androgens in the dynamics of folliculogenesis. It challenges the idea that androgens induce high AMH levels, which is gaining more interest nowadays as an important particular PCOS feature. This strong decline furthermore indicates that AMH must be interpreted in the context of other reproductive endocrine conditions. CLINICAL TRIAL REGISTRATION NUMBER: NTR2493.
Authors: Maria Yan; Samyd S Bustos; Doga Kuruoglu; Pedro Ciudad; Antonio J Forte; Esther A Kim; Gabriel Del Corral; Oscar J Manrique Journal: Ann Transl Med Date: 2021-04
Authors: Amy C Tishelman; Megan E Sutter; Diane Chen; Amani Sampson; Leena Nahata; Victoria D Kolbuck; Gwendolyn P Quinn Journal: J Assist Reprod Genet Date: 2019-01-03 Impact factor: 3.412
Authors: Cecily V Bishop; Diana Takahashi; Emily Mishler; Ov D Slayden; Charles T Roberts; Jon Hennebold; Cadence True Journal: Hum Reprod Date: 2021-01-25 Impact factor: 6.918
Authors: Frances W Grimstad; Kylie G Fowler; Erika P New; Cecile A Ferrando; Robert R Pollard; Graham Chapman; Meredith Gray; Veronica Gomez Lobo Journal: J Sex Med Date: 2020-07-20 Impact factor: 3.802